ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.909,14
-0,25%
S&P 500
5.906,94
-1,07%
Dow Jones
42.573,73
-0,97%
Euro vs US Dollar
1,04086
0,03%
Bitcoin
92.573,15
-0,10%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE

  6. Annovis Bio Inc (ANVS) Börsenkurse

Annovis Bio Inc

Annovis Bio Inc (ANVS)

NYSE
5,08
-0,19
(-3,61%)
Geschlossen 31 Dezember 10:00PM
Verzögert um 15 Minuten
5,05
-0,03
(-0,59%)
Nach Börsenschluss: 1:51AM
Verzögert um 15 Minuten

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
5,05
Gebot
-
Fragen
-
Volumen
177.445
5,04 Tagesbereich 5,305
4,21 52-Wochen-Bereich 20,00
Marktkapitalisierung
69,676M
Handelsende
5,27
Handelsbeginn
5,215
Letzte Trade
3528
@
5.08
Letzter Handelszeitpunkt
Finanzvolumen
US$ 919.646
VWAP
5,1827
Durchschnittliches Volumen (3 Mio.)
297.834
Ausgegebene Aktien
13.797.242
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-1,25
Gewinn pro Aktie (EPS)
-4,07
Erlöse
-
Nettogewinn
-56,2M

Über Annovis Bio Inc

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301. Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.annovisbio.com
Hauptsitz
Dover, Delaware, USA
Gegründet
-
Annovis Bio Inc is listed in the Pharmaceutical Preparations sector of the New York Börse with ticker ANVS. The last closing price for Annovis Bio was US$5,27. Over the last year, Annovis Bio shares have traded in a share price range of US$ 4,21 to US$ 20,00.

Annovis Bio currently has 13.797.242 shares in issue. The market capitalisation of Annovis Bio is US$72,71 million. Annovis Bio has a price to earnings ratio (PE ratio) of -1.25.

Option-Flow Annovis Bio (ANVS)

Vollständigen Option-Flow anzeigen

Gesamtfluss

Bärisch

Nettoprämie

-35k

Calls / Puts

0,00%

Käuf. / Verkä.

0,00%

OTM / ITM

0,00%

Sweeps

0,00%

ANVS Neueste Nachrichten

Weitere Nachrichten

Form 8-K - Current report

11 Dezember 2024
Edgar (US Regulatory)

Form 8-K - Current report

09 Dezember 2024
Edgar (US Regulatory)

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace

LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is...

05 Dezember 2024
GlobeNewswire Inc.

Form 8-K - Current report

12 November 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

08 November 2024
Edgar (US Regulatory)

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to...

31 Oktober 2024
GlobeNewswire Inc.

Form 8-K - Current report

15 Oktober 2024
Edgar (US Regulatory)

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

October 3, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring...

03 Oktober 2024
InvestorsHub NewsWire

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

October 2, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as...

02 Oktober 2024
InvestorsHub NewsWire

Form 8-K - Current report

30 September 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.6314.25339366524.425.344.212851295.02329473CS
4-1.76-25.84434654926.817.394.213330055.47751367CS
12-3.24-39.08323281068.2910.544.212978347.27226539CS
26-0.94-15.69282136895.9917.884.21100426910.60740523CS
52-13.95-73.421052631619204.2170678810.13170669CS
156-12.73-71.597300337517.7823.90994.2128756110.73057824CS
260-3.9375-43.81084840068.98751322.41834960425.22411054CS

ANVS - Frequently Asked Questions (FAQ)

What is the current Annovis Bio share price?
The current share price of Annovis Bio is US$ 5,05
How many Annovis Bio shares are in issue?
Annovis Bio has 13.797.242 shares in issue
What is the market cap of Annovis Bio?
The market capitalisation of Annovis Bio is USD 72,71M
What is the 1 year trading range for Annovis Bio share price?
Annovis Bio has traded in the range of US$ 4,21 to US$ 20,00 during the past year
What is the PE ratio of Annovis Bio?
The price to earnings ratio of Annovis Bio is -1,25
What is the reporting currency for Annovis Bio?
Annovis Bio reports financial results in USD
What is the latest annual profit for Annovis Bio?
The latest annual profit of Annovis Bio is USD -56,2M
What is the registered address of Annovis Bio?
The registered address for Annovis Bio is 1111B S GOVERNORS AVENUE, KENT, DOVER, DELAWARE, 19904
What is the Annovis Bio website address?
The website address for Annovis Bio is www.annovisbio.com
Which industry sector does Annovis Bio operate in?
Annovis Bio operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
VHCVirnetX Holding Corp
US$ 8,89
(69,33%)
478,59k
PERFPerfect Corp
US$ 3,27
(28,24%)
1,25M
STEMStem Inc
US$ 0,7558
(27,11%)
67,14M
AMPXAmprius Technologies Inc
US$ 2,97
(25,85%)
11,52M
BBAIBigBear ai Holdings Inc
US$ 4,825
(14,61%)
76,08M
EVTLVertical Aerospace Ltd
US$ 12,54
(-19,10%)
547,78k
MPLNChurchill Capital Corp III
US$ 14,85
(-15,24%)
259,69k
DNMRDanimer Scientific Inc
US$ 4,06
(-13,98%)
211,63k
EXTOAlmacenes Exito SA
US$ 3,17
(-11,20%)
302,09k
FREYFREYR Battery Inc
US$ 2,70
(-10,89%)
4,4M
BBAIBigBear ai Holdings Inc
US$ 4,825
(14,61%)
76,08M
STEMStem Inc
US$ 0,7558
(27,11%)
67,14M
ABEVAmbev SA
US$ 1,85
(-1,07%)
59,6M
QBTSD Wave Quantum Inc
US$ 9,30
(-6,16%)
57,61M
FFord Motor Company
US$ 9,87
(-1,60%)
47,1M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NYSE
ANVS
Annovis Bio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten